A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplat recipients: 10,000/μL versus 20,000/μL trigger

Marc S. Zumberg, Maria Luz U Del Rosario, Christine F. Nejame, Bradley H Pollock, Linda Garzarella, K. J. Kao, Richard Lottenberg, John R. Wingard

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

An optimal platelet-count threshold for prophylactic platelet transfusion in hematopoietic stem cell transplant (HSCT) recipients has yet to be determined. Between July 1997 and December 1999, we performed the first prospective randomized clinical trial addressing this issue in 159 HSCT recipients who received a prophylactic platelet transfusion when the morning platelet count fell below a 10,000/μL (10K) or 20,000/μL (20K) threshold. Subsequent prophylactic transfusions were administered according to a predetermined algorithm. The number of prophylactic and therapeutic transfusions and the incidence of minor and major bleeding were compared between the 2 groups. The groups were matched according to patient and transplantation characteristics. There were no significant differences in bleeding incidence or severity. Fourteen percent of patients in the 10K arm compared to 17% in the 20K arm had major bleeding events. Only 3 central nervous system bleeds occurred, 2 in the 10K group and 1 in the 20K group. No deaths were attributed to bleeding. An average of 11.4 days of bleeding occurred in both groups. An average of 10.4 platelet transfusions per patient were administered in the 10K group compared to 10.2 in the 20K group (P = .94). More transfusions were given above the assigned transfusion threshold in the 10K group than in the 20K group (4.3/patient versus 1.9/patient, respectively, P = .05). Safety measures incorporated into our study may have precluded demonstration of significant differences in platelet use between the groups. In conclusion, a platelet transfusion trigger of 10K was found to be safe; however, a decrease in platelet use was not achieved because of safety measures incorporated into our study design.

Original languageEnglish (US)
Pages (from-to)569-576
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume8
Issue number10
StatePublished - 2002
Externally publishedYes

Fingerprint

Platelet Transfusion
Hematopoietic Stem Cells
Hemorrhage
Incidence
Platelet Count
Arm
Blood Platelets
Transplants
Safety
Research Design
Central Nervous System
Randomized Controlled Trials
Transplantation

Keywords

  • Bleeding
  • Platelet transfusion threshold
  • Stem cell transplant
  • Trigger

ASJC Scopus subject areas

  • Transplantation

Cite this

A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplat recipients : 10,000/μL versus 20,000/μL trigger. / Zumberg, Marc S.; Del Rosario, Maria Luz U; Nejame, Christine F.; Pollock, Bradley H; Garzarella, Linda; Kao, K. J.; Lottenberg, Richard; Wingard, John R.

In: Biology of Blood and Marrow Transplantation, Vol. 8, No. 10, 2002, p. 569-576.

Research output: Contribution to journalArticle

Zumberg, Marc S. ; Del Rosario, Maria Luz U ; Nejame, Christine F. ; Pollock, Bradley H ; Garzarella, Linda ; Kao, K. J. ; Lottenberg, Richard ; Wingard, John R. / A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplat recipients : 10,000/μL versus 20,000/μL trigger. In: Biology of Blood and Marrow Transplantation. 2002 ; Vol. 8, No. 10. pp. 569-576.
@article{e96bd20b88da4960b005c767d30f50d7,
title = "A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplat recipients: 10,000/μL versus 20,000/μL trigger",
abstract = "An optimal platelet-count threshold for prophylactic platelet transfusion in hematopoietic stem cell transplant (HSCT) recipients has yet to be determined. Between July 1997 and December 1999, we performed the first prospective randomized clinical trial addressing this issue in 159 HSCT recipients who received a prophylactic platelet transfusion when the morning platelet count fell below a 10,000/μL (10K) or 20,000/μL (20K) threshold. Subsequent prophylactic transfusions were administered according to a predetermined algorithm. The number of prophylactic and therapeutic transfusions and the incidence of minor and major bleeding were compared between the 2 groups. The groups were matched according to patient and transplantation characteristics. There were no significant differences in bleeding incidence or severity. Fourteen percent of patients in the 10K arm compared to 17{\%} in the 20K arm had major bleeding events. Only 3 central nervous system bleeds occurred, 2 in the 10K group and 1 in the 20K group. No deaths were attributed to bleeding. An average of 11.4 days of bleeding occurred in both groups. An average of 10.4 platelet transfusions per patient were administered in the 10K group compared to 10.2 in the 20K group (P = .94). More transfusions were given above the assigned transfusion threshold in the 10K group than in the 20K group (4.3/patient versus 1.9/patient, respectively, P = .05). Safety measures incorporated into our study may have precluded demonstration of significant differences in platelet use between the groups. In conclusion, a platelet transfusion trigger of 10K was found to be safe; however, a decrease in platelet use was not achieved because of safety measures incorporated into our study design.",
keywords = "Bleeding, Platelet transfusion threshold, Stem cell transplant, Trigger",
author = "Zumberg, {Marc S.} and {Del Rosario}, {Maria Luz U} and Nejame, {Christine F.} and Pollock, {Bradley H} and Linda Garzarella and Kao, {K. J.} and Richard Lottenberg and Wingard, {John R.}",
year = "2002",
language = "English (US)",
volume = "8",
pages = "569--576",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplat recipients

T2 - 10,000/μL versus 20,000/μL trigger

AU - Zumberg, Marc S.

AU - Del Rosario, Maria Luz U

AU - Nejame, Christine F.

AU - Pollock, Bradley H

AU - Garzarella, Linda

AU - Kao, K. J.

AU - Lottenberg, Richard

AU - Wingard, John R.

PY - 2002

Y1 - 2002

N2 - An optimal platelet-count threshold for prophylactic platelet transfusion in hematopoietic stem cell transplant (HSCT) recipients has yet to be determined. Between July 1997 and December 1999, we performed the first prospective randomized clinical trial addressing this issue in 159 HSCT recipients who received a prophylactic platelet transfusion when the morning platelet count fell below a 10,000/μL (10K) or 20,000/μL (20K) threshold. Subsequent prophylactic transfusions were administered according to a predetermined algorithm. The number of prophylactic and therapeutic transfusions and the incidence of minor and major bleeding were compared between the 2 groups. The groups were matched according to patient and transplantation characteristics. There were no significant differences in bleeding incidence or severity. Fourteen percent of patients in the 10K arm compared to 17% in the 20K arm had major bleeding events. Only 3 central nervous system bleeds occurred, 2 in the 10K group and 1 in the 20K group. No deaths were attributed to bleeding. An average of 11.4 days of bleeding occurred in both groups. An average of 10.4 platelet transfusions per patient were administered in the 10K group compared to 10.2 in the 20K group (P = .94). More transfusions were given above the assigned transfusion threshold in the 10K group than in the 20K group (4.3/patient versus 1.9/patient, respectively, P = .05). Safety measures incorporated into our study may have precluded demonstration of significant differences in platelet use between the groups. In conclusion, a platelet transfusion trigger of 10K was found to be safe; however, a decrease in platelet use was not achieved because of safety measures incorporated into our study design.

AB - An optimal platelet-count threshold for prophylactic platelet transfusion in hematopoietic stem cell transplant (HSCT) recipients has yet to be determined. Between July 1997 and December 1999, we performed the first prospective randomized clinical trial addressing this issue in 159 HSCT recipients who received a prophylactic platelet transfusion when the morning platelet count fell below a 10,000/μL (10K) or 20,000/μL (20K) threshold. Subsequent prophylactic transfusions were administered according to a predetermined algorithm. The number of prophylactic and therapeutic transfusions and the incidence of minor and major bleeding were compared between the 2 groups. The groups were matched according to patient and transplantation characteristics. There were no significant differences in bleeding incidence or severity. Fourteen percent of patients in the 10K arm compared to 17% in the 20K arm had major bleeding events. Only 3 central nervous system bleeds occurred, 2 in the 10K group and 1 in the 20K group. No deaths were attributed to bleeding. An average of 11.4 days of bleeding occurred in both groups. An average of 10.4 platelet transfusions per patient were administered in the 10K group compared to 10.2 in the 20K group (P = .94). More transfusions were given above the assigned transfusion threshold in the 10K group than in the 20K group (4.3/patient versus 1.9/patient, respectively, P = .05). Safety measures incorporated into our study may have precluded demonstration of significant differences in platelet use between the groups. In conclusion, a platelet transfusion trigger of 10K was found to be safe; however, a decrease in platelet use was not achieved because of safety measures incorporated into our study design.

KW - Bleeding

KW - Platelet transfusion threshold

KW - Stem cell transplant

KW - Trigger

UR - http://www.scopus.com/inward/record.url?scp=0036433219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036433219&partnerID=8YFLogxK

M3 - Article

C2 - 12434952

AN - SCOPUS:0036433219

VL - 8

SP - 569

EP - 576

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 10

ER -